CompletedPhase 2NCT04389671

The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)

Studying Adult acute respiratory distress syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Windtree Therapeutics
Principal Investigator
Yuh-Chin T Huang, MD, MHS
Duke University
Intervention
Lucinactant(drug)
Enrollment
20 enrolled
Eligibility
18-75 years · All sexes
Timeline
20212022

Study locations (11)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04389671 on ClinicalTrials.gov

Other trials for Adult acute respiratory distress syndrome

Additional recruiting or active studies for the same condition.

See all trials for Adult acute respiratory distress syndrome

← Back to all trials